Advertisement

Topics

Isogenica Ltd and Fusion Pharmaceuticals Inc Company Profile

23:23 EDT 24th September 2018 | BioPortfolio

Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. Partners can access an advanced camelid single-domain antibody library (llamdA™) and state-of-the-art, fully synthetic and highly diverse human Fab antibody libraries (Alexandria™). The company uses its proprietary Colibra™ library technology to ensure that the libraries very accurately reflect its advanced designs. Libraries can be screened in various formats, including phage and CIS Display, a proprietary in vitro display technology which maintains the high diversity of the llamdA™ libraries through the discovery process. CIS Display is also available as a stand-alone polypeptide display technology.


News Articles [555 Associated News Articles listed on BioPortfolio]

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology

Technology will be used to progress Fusion’s pipeline of alpha therapeutics for the treatment of cancers Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announce...

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology - Technology will be used to progress Fusion’s pipeline of alpha therapeutics for the treatment of cancers

   Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage each other&rsqu...

Fusion to identify cancer candidates with Isogenica platform

Isogenica Licenses CIS Display Technology to Aro Biotherapeutics for Centyrin-based Biopharmaceutical Development

Isogenica Ltd today announced that it has signed a new licensing agreement with Aro Biotherapeutics Company (Aro) of Philadelphia. USA, that will leverage each other’s strengths...

Isogenica Ltd licenses CIS Display Technology to Aro Biotherapeutics for Centyrin-based biopharmaceutical development

Cambridge, UK, 23rd July 2018: Isogenica Ltd today announced that it has signed a new licensing agreement with Aro Biotherapeutics Company (Aro) of Philadelphia. USA, that will leverage each othe...

New MIT Startup Targets Working Fusion Reactor in 15 Years. Can It Be Done?

The joke is that nuclear fusion is 20 years away, and always will be. This joke, now a cliché, arose from optimistic scientists suggesting in the 1950s (and then in most subsequent decades) that nucl...

Fusion att vänta

Oncology Venture och Medical Prognosis Institute planerar fusion av bolagen. Vill skapa "one stop shop".

Vatics Standardizes on Synopsys' Fusion Technology for its Next-Generation Multimedia SoC Design

Fusion Technology enables Vatics to achieve highest design performance while eliminating ECO iterations on their 28-nm multimedia SoC design ECO Fusion delivers signoff accuracy during Read...

PubMed Articles [835 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Single-Molecule Analysis of a Viral Fusion Protein Illuminates a Fusion-Active Intermediate State.

The influenza virus hemagglutinin (HA) fusion glycoprotein mediates viral entry into host cells through its receptor binding and membrane fusion activities. In this issue of Cell, Das et al. use sing...

Phases of the exocytotic fusion pore.

Membrane fusion and fission are fundamental processes in living organisms. Membrane fusion occurs through the formation of a fusion pore, which is the structure that connects two lipid membranes durin...

Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia.

Fusion genes are major molecular biological abnormalities in hematological malignancies. To depict the common recurrent gene-fusion landscape in acute lymphoblastic leukemia (ALL), 36 recurrent fusion...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Clinical Trials [699 Associated Clinical Trials listed on BioPortfolio]

Comparative Study Between Posterior Lumbar Interbody Fusion(PLIF) and Intertransverse Process Fusion in Treatment of Spodylolithesis

The first technique described for interbody fusion was the anterior lumbar interbody fusion (ALIF).(20) For this technique, the intervertebral disc is accessed through a retroperitoneal or...

A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine

The purpose of this study is - to evaluate the effectiveness of MAST techniques for anterior/lateral and posterior approaches in patients with spondylolisthesis (≥ grade I). ...

Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft

The purpose of this study is to compare Optecure™ as an autograft extender (treatment) to autograft alone (control) in patients undergoing 1 or 2 level fusion of the lumbar spine(one lev...

ViBone in Cervical and Lumbar Spine Fusion

Assess clinical and radiographic outcomes in patients who undergo anterior cervical discectomy fusion (ACDF), transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fu...

Spinal Fusion Study

The aim of the present study is to analyse the significance of postoperative combined strength and aerobic training for outcome of the lumbar fusion patients compared to usual care (patien...

Companies [1453 Associated Companies listed on BioPortfolio]

Isogenica Ltd and Fusion Pharmaceuticals Inc

Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. P...

Fusion Pharmaceuticals

Fusion Pharmaceuticals is a new pharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit...

Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusio...

Practice Fusion Inc.

Practice Fusion addresses the complexities and critical needs of today's healthcare environments by providing a revolutionary free, web-based electronic health record (EHR) application and delivery mo...

Kareo

Practice Fusion provides a free, web-based Electronic Health Record (EHR) system to physicians. With charting, scheduling, e-prescribing, billing, lab integrations, unlimited support and a Personal He...

More Information about "Isogenica Ltd and Fusion Pharmaceuticals Inc" on BioPortfolio

We have published hundreds of Isogenica Ltd and Fusion Pharmaceuticals Inc news stories on BioPortfolio along with dozens of Isogenica Ltd and Fusion Pharmaceuticals Inc Clinical Trials and PubMed Articles about Isogenica Ltd and Fusion Pharmaceuticals Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Isogenica Ltd and Fusion Pharmaceuticals Inc Companies in our database. You can also find out about relevant Isogenica Ltd and Fusion Pharmaceuticals Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record